Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up
Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up
复制标题
DOI：
10.1128/jcm.42.1.242-249.2004
复制
发表时间：
2004-01-01
影响因子：
9.4
通讯作者：
Zandotti, C
中科院分区：
文献类型：
--
作者：
Danve-Szatanek, C;Aymard, M;Zandotti, C
单纯疱疹病毒(HSV)感染在普通人群和免疫功能低下的患者中非常常见。阿昔洛韦(Acylovir，ACV)是一种应用广泛的有效治疗药物。我们认为有必要对抗阿昔洛韦的单纯疱疹病毒株的出现进行广泛和协调的调查。我们已经形成了由15个病毒学实验室组成的网络，这些实验室在1999年5月至2002年4月期间在住院受试者中分离和鉴定了1型单纯疱疹病毒(HSV-1)和2型单纯疱疹病毒(HSV-2)毒株。通过比色试验(C.Danve，F.Morfin，D.Thouvenot和M.Aymard，J.Virol)评估每个分离物对ACV的敏感性。方法：105：207-217,2002)。在这项研究中，从3357名患者中收集了3900株分离株；55%的患者具有免疫活性。只有6名免疫功能正常的患者排泄出对阿昔洛韦耐药的HSV株(0.32%)，包括1名未接受阿昔洛韦治疗的女性患者，她是由阿昔洛韦耐药株初次感染的。在分离出抗阿昔洛韦HSV株的54例免疫低下患者中，骨髓移植患者的耐药率最高(10.9%)，而在感染人类免疫缺陷病毒的患者中，耐药率为4.2%。在38%的病例中，排出ACV耐药株的患者接受了磷甲酸钠(PFA)治疗，其中61%的患者对PFA产生了耐药性。大量分离株的收集使得对HSV株对抗病毒药物的耐药性的流行率进行了评估。在过去的10年里，这种流行率保持稳定，在免疫能力强的患者中和免疫功能低下的患者中一样多。
Herpes simplex virus (HSV) infections are very common in the general population and among immunocompromised patients. Acyclovir (ACV) is an effective treatment which is widely used. We deemed it essential to conduct a wide and coordinated survey of the emergence of ACV-resistant HSV strains. We have formed a network of 15 virology laboratories which have isolated and identified, between May 1999 and April 2002, HSV type 1 (HSV-1) and HSV-2 strains among hospitalized subjects. The sensitivity of each isolate to ACV was evaluated by a colorimetric test (C. Danve, F. Morfin, D. Thouvenot, and M. Aymard, J. Virol. Methods 105:207-217, 2002). During this study, 3,900 isolated strains among 3,357 patients were collected; 55% of the patients were immunocompetent. Only six immunocompetent patients excreted ACV-resistant HSV strains (0.32%), including one female patient not treated with ACV who was infected primary by an ACV-resistant strain. Among the 54 immunocompromised patients from whom ACV-resistant HSV strains were isolated (3.5%), the bone marrow transplantation patients showed the highest prevalence of resistance (10.9%), whereas among patients infected by human immunodeficiency virus, the prevalence was 4.2%. In 38% of the cases, the patients who excreted the ACV-resistant strains were treated with foscarnet (PFA), and 61% of them developed resistance to PFA. The collection of a large number of isolates enabled an evaluation of the prevalence of resistance of HSV strains to antiviral drugs to be made. This prevalence has remained stable over the last 10 years, as much among immunocompetent patients as among immunocompromised patients.